Curtis G. Oltmans J.D.
Net Worth
Last updated:
What is Curtis G. Oltmans J.D. net worth?
The estimated net worth of Mr. Curtis G. Oltmans J.D. is at least $342,894 as of 28 Jun 2021. He owns shares worth $6,974 as insider and has received compensation worth at least $335,920 in Fulcrum Therapeutics, Inc..
What is the salary of Curtis G. Oltmans J.D.?
Mr. Curtis G. Oltmans J.D. salary is $83,980 per year as Senior Vice President, Gen. Counsel & Corporation Sec. in Fulcrum Therapeutics, Inc..
How old is Curtis G. Oltmans J.D.?
Mr. Curtis G. Oltmans J.D. is 62 years old, born in 1963.
What stocks does Curtis G. Oltmans J.D. currently own?
As insider, Mr. Curtis G. Oltmans J.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | Senior Vice President, Gen. Counsel & Corporation Sec. | 1,088 | $6.41 | $6,974 |
What does Fulcrum Therapeutics, Inc. do?
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Curtis G. Oltmans J.D. insider trading
Fulcrum Therapeutics key executives
Fulcrum Therapeutics, Inc. executives and other stock owners filed with the SEC:
- Mr. Bryan E. Stuart (49) Pres, Chief Executive Officer & Director
- Mr. Curtis G. Oltmans J.D. (62) Senior Vice President, Gen. Counsel & Corporation Sec.
- Mr. Mark J. Levin (75) Executive Chairman